# To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis

> **NCT02057250** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 217 (actual)

## Conditions studied

- RA

## Interventions

- **DRUG:** Sarilumab
- **DEVICE:** Auto-Injector Device (AID)
- **DEVICE:** Pre-filled Syringe (PFS)
- **DRUG:** Methotrexate
- **DRUG:** Sulfasalazine
- **DRUG:** Leflunomide
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT02057250
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-02
- **Final completion:** 2016-03
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2017-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02057250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02057250, "To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02057250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*